NR4A1 and breast cancer: Intrinsic or subsequently acquired resistance to endocrine therapy continues to be a major obstacle in the therapy for hormone receptor‐positive BC (Szostakowska, Trebinska‐Stryjewska, Grzybowska, & Fabisiewicz, 2019).